Results 1 to 10 of about 166,676 (142)

Acute myeloid leukemia with <i>DEK::NUP214</i> fusion resembling acute promyelocytic leukemia, initially presenting as sweet syndrome: A case report and literature review. [PDF]

J Int Med Res
Some subtypes of acute myeloid leukemia share morphologic, immunophenotypic, and clinical features of acute promyelocytic leukemia but lack a promyelocytic leukemia–retinoic acid receptor alpha fusion gene.
Liu H, Liu GX, Liu FH, Wang SG.
europepmc   +2 more sources

Long-term experience in treatment of acute promyelocytic leukemia in Mexican children in a tertiary care hospital

Frontiers in Oncology, 2023
IntroductionAcute promyelocytic leukemia (APL) is a rare myeloid leukemia subtype affecting adult and pediatric populations. APL constitutes 15-20% of all childhood AML in Latin America, compared to 7% in the non-Latino population.
Marco Antonio Murillo-Maldonado, Paulina González Galván, Israel Parra Ortega, Félix Gaytán Morales, Félix Gaytán Morales, Luis Juárez Villegas, Elisa Dorantes Acosta, Elisa Dorantes Acosta   +7 more
doaj   +1 more source

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

Haematologica, 2021
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic
Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, S. Tiong Ong   +4 more
doaj   +1 more source

Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

HemaSphere, 2021
Tyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation ...
Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf, Lurdes Zamora   +12 more
doaj   +1 more source

Socioeconomic cost of AML in Sweden—A population‐based study using multiple nation‐wide registers

eJHaem, 2021
Acute myeloid leukemia (AML) is associated with a high economic and clinical burden. Recently novel therapies have been added to standard treatment regimens. Here, we evaluated the economic impact of AML up until the introduction of these novel therapies.
Emma Hernlund, Josefine Redig, Björn Paulsson, Åsa Rangert Derolf, Martin Höglund, Simona Vertuani, Gunnar Juliusson   +6 more
doaj   +1 more source

Acute myeloid leukemia: update in diagnosis and treatment in Brazil [PDF]

Einstein (São Paulo), 2011
Objective: To identify how the Brazilian hematology centers treated and diagnosed cases of acute myeloid leukemia in 2009. Methods: An epidemiological observational multicenter study of 11 listed Brazilian centers that treat acute myeloid leukemia and ...
Ricardo Helman, Fabio Pires de Souza Santos, Belinda Simões, Elias Hallack Atta, Fernando Callera, Jane de Almeida Dobbin, Éderson Roberto Mattos, Angelo Atalla, Angelo Maiolino, Maria Aparecida Zanichelli, Cristiane Fração Diefenbach, Marcia Torresan Delamain, Nelson Hamerschlak   +12 more
doaj   +3 more sources

Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice

Haematologica, 2008
We investigated the NPM1 mutation status or subcellular expression of NPM protein (nuclear vs. aberrant cytoplasmic) at diagnosis and relapse in 125 patients with acute myeloid leukemia from Italy and Germany.
Brunangelo Falini, Maria Paola Martelli, Cristina Mecucci, Arcangelo Liso, Niccolò Bolli, Barbara Bigerna, Alessandra Pucciarini, Stefano Pileri, Giovanna Meloni, Massimo F. Martelli, Torsten Haferlach, Susanne Schnittger   +11 more
doaj   +1 more source

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Haematologica, 2019
Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia. However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies are negligible in acute myeloid ...
Jianbiao Zhou, Jessie Yiying Quah, Yvonne Ng, Jing-Yuan Chooi, Sabrina Hui-Min Toh, Baohong Lin, Tuan Zea Tan, Hiroki Hosoi, Motomi Osato, Qihui Seet, A.G. Lisa Ooi, Bertil Lindmark, Mark McHale, Wee-Joo Chng   +13 more
doaj   +1 more source

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

Haematologica, 2011
Background The World Health Organization separates acute erythroid leukemia (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis – acute myeloid leukemia with ...
Ulrike Bacher, Claudia Haferlach, Tamara Alpermann, Wolfgang Kern, Susanne Schnittger, Torsten Haferlach   +5 more
doaj   +1 more source

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

Haematologica, 2008
Acute myeloid leukemia carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ acute myeloid leukemia) represents one-third of adult AML (50–60% of all acute myeloid leukemia with normal karyotype) and shows distinct biological, pathological and ...
Brunangelo Falini, Cristina Mecucci, Giuseppe Saglio, Francesco Lo Coco, Daniela Diverio, Patrick Brown, Fabrizio Pane, Marco Mancini, Maria Paola Martelli, Stefano Pileri, Torsten Haferlach, Claudia Haferlach, Susanne Schnittger   +12 more
doaj   +1 more source